Prevalence and epidemiology of stroke in patients with multiple sclerosis: a systematic review and meta-analysis.
Cardiovascular risk factors
Cerebrovascular disease
Intracerebral haemorrhage
Multiple sclerosis
Stroke
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
04 Apr 2024
04 Apr 2024
Historique:
received:
07
02
2024
accepted:
11
03
2024
revised:
09
03
2024
medline:
4
4
2024
pubmed:
4
4
2024
entrez:
4
4
2024
Statut:
aheadofprint
Résumé
Epidemiological data are sparse regarding the risk of stroke in patients with multiple sclerosis (MS). To estimate the following: (1) the pooled prevalence of all-cause stroke, acute ischaemic stroke (AIS) and intracerebral haemorrhage (ICH) in MS patients; (2) the relative risk for all-cause stroke, AIS and ICH in MS patients compared to the general population; (3) associations between patient characteristics and the risk for AIS and ICH in MS patients. Systematic review and meta-analysis of registry-based and cohort studies. Thirteen observational studies comprising 146,381 MS patients were included. The pooled prevalence of all-cause stroke was 2.7% (95% confidence interval [CI] 1.3-4.6%), with the relative risk of all-cause stroke being higher in MS patients compared to the general population (RR: 2.55; 95% CI 1.97-3.29). Subgroup analyses per stroke subtype revealed a pooled AIS prevalence of 2.1% (95% CI 0.8-4.1%) and a pooled ICH prevalence of 0.6% (95% CI 0.2-1.2%). Compared to the general population, patients with MS were found to harbour an increased risk for AIS (RR: 2.79; 95% CI 2.27-3.41) and ICH (RR: 2.31; 95% CI 1.04-5.11), respectively. The pooled prevalence of cardiovascular risk factors in MS patients was 11.5% (95% CI 2.9-24.7%) for dyslipidaemia, 18.2% (95% CI 5.9-35.3%) for hypertension and 5.4% (95% CI 2.1-10.2%) for diabetes. In meta-regression, age was negatively associated with AIS risk (β = - .03, p = 0.04), with a 1-year increase in age resulting in a significant 3% (95%CI 0-5) attenuation of the risk of AIS. The findings of the present meta-analysis indicate that MS is associated with an increased risk for ischaemic and haemorrhagic stroke. Future well-designed epidemiological studies are warranted to corroborate the robustness of the present findings in the MS population.
Sections du résumé
BACKGROUND
BACKGROUND
Epidemiological data are sparse regarding the risk of stroke in patients with multiple sclerosis (MS).
OBJECTIVE
OBJECTIVE
To estimate the following: (1) the pooled prevalence of all-cause stroke, acute ischaemic stroke (AIS) and intracerebral haemorrhage (ICH) in MS patients; (2) the relative risk for all-cause stroke, AIS and ICH in MS patients compared to the general population; (3) associations between patient characteristics and the risk for AIS and ICH in MS patients.
METHODS
METHODS
Systematic review and meta-analysis of registry-based and cohort studies.
RESULTS
RESULTS
Thirteen observational studies comprising 146,381 MS patients were included. The pooled prevalence of all-cause stroke was 2.7% (95% confidence interval [CI] 1.3-4.6%), with the relative risk of all-cause stroke being higher in MS patients compared to the general population (RR: 2.55; 95% CI 1.97-3.29). Subgroup analyses per stroke subtype revealed a pooled AIS prevalence of 2.1% (95% CI 0.8-4.1%) and a pooled ICH prevalence of 0.6% (95% CI 0.2-1.2%). Compared to the general population, patients with MS were found to harbour an increased risk for AIS (RR: 2.79; 95% CI 2.27-3.41) and ICH (RR: 2.31; 95% CI 1.04-5.11), respectively. The pooled prevalence of cardiovascular risk factors in MS patients was 11.5% (95% CI 2.9-24.7%) for dyslipidaemia, 18.2% (95% CI 5.9-35.3%) for hypertension and 5.4% (95% CI 2.1-10.2%) for diabetes. In meta-regression, age was negatively associated with AIS risk (β = - .03, p = 0.04), with a 1-year increase in age resulting in a significant 3% (95%CI 0-5) attenuation of the risk of AIS.
CONCLUSION
CONCLUSIONS
The findings of the present meta-analysis indicate that MS is associated with an increased risk for ischaemic and haemorrhagic stroke. Future well-designed epidemiological studies are warranted to corroborate the robustness of the present findings in the MS population.
Identifiants
pubmed: 38573365
doi: 10.1007/s00415-024-12331-2
pii: 10.1007/s00415-024-12331-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Strober LB, Christodoulou C, Benedict RH, Westervelt HJ, Melville P, Scherl WF, Weinstock-Guttman B, Rizvi S, Goodman AD, Krupp LB (2012) Unemployment in multiple sclerosis: the contribution of personality and disease. Mult Scler 18:647–653
pubmed: 22183935
doi: 10.1177/1352458511426735
Koch-Henriksen N, Sørensen PS (2010) The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 9:520–532
pubmed: 20398859
doi: 10.1016/S1474-4422(10)70064-8
Leray E, Moreau T, Fromont A, Edan G (2016) Epidemiology of multiple sclerosis. Rev Neurol (Paris) 172:3–13
pubmed: 26718593
doi: 10.1016/j.neurol.2015.10.006
Lublin FD, Häring DA, Ganjgahi H, Ocampo A, Hatami F, Čuklina J, Aarden P, Dahlke F, Arnold DL, Wiendl H, Chitnis T, Nichols TE, Kieseier BC, Bermel RA (2022) How patients with multiple sclerosis acquire disability. Brain 145:3147–3161
pubmed: 35104840
pmcid: 9536294
doi: 10.1093/brain/awac016
Spencer JI, Bell JS, DeLuca GC (2018) Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier. J Neurol Neurosurg Psychiatry 89:42–52
pubmed: 28860328
doi: 10.1136/jnnp-2017-316011
Geraldes R, Esiri MM, Perera R, Yee SA, Jenkins D, Palace J, DeLuca GC (2020) Vascular disease and multiple sclerosis: a post-mortem study exploring their relationships. Brain 143:2998–3012
pubmed: 32875311
doi: 10.1093/brain/awaa255
Marrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T (2010) Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 74:1041–1047
pubmed: 20350978
pmcid: 2848107
doi: 10.1212/WNL.0b013e3181d6b125
Kaplan TB, Berkowitz AL, Samuels MA (2015) Cardiovascular dysfunction in multiple sclerosis. Neurologist 20:108–114
pubmed: 26671744
doi: 10.1097/NRL.0000000000000064
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Moher D (2021) Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol 134:103–112
pubmed: 33577987
doi: 10.1016/j.jclinepi.2021.02.003
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012
pubmed: 10789670
doi: 10.1001/jama.283.15.2008
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919
pubmed: 27733354
pmcid: 5062054
doi: 10.1136/bmj.i4919
Giannopapas V, Palaiodimou L, Kitsos D, Papagiannopoulou G, Stavrogianni K, Chasiotis A, Kosmidou M, Tzartos JS, Paraskevas GP, Bakalidou D, Tsivgoulis G, Giannopoulos S (2023) The prevalence of Diabetes Mellitus Type II (DMII) in the Multiple sclerosis population: a systematic review and meta-analysis. J Clin Med 12:4948
pubmed: 37568348
pmcid: 10420178
doi: 10.3390/jcm12154948
Stefanou MI, Palaiodimou L, Katsanos AH, Milionis H, Kosmidou M, Lambadiari V, Halvatsiotis P, Ferentinos P, Andreadou E, Marinos G, Theodorou A, Tzartos JS, Voumvourakis K, Tsivgoulis G, Giannopoulos S (2022) The effects of HMG-CoA reductase inhibitors on disease activity in multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord 58:103395
pubmed: 35216778
doi: 10.1016/j.msard.2021.103395
Freeman MF, Tukey JW (1950) Transformations related to the angular and the square root. Annals Math Stat 607–611
Tsivgoulis G, Katsanos AH, Köhrmann M, Caso V, Perren F, Palaiodimou L, Deftereos S, Giannopoulos S, Ellul J, Krogias C (2019) Duration of implantable cardiac monitoring and detection of atrial fibrillation in ischemic stroke patients: a systematic review and meta-analysis. J Stroke 21:302
pubmed: 31590474
pmcid: 6780018
doi: 10.5853/jos.2019.01067
Borenstein M, Higgins JP (2013) Meta-analysis and subgroups. Prev Sci 14:134–143
pubmed: 23479191
doi: 10.1007/s11121-013-0377-7
Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
pubmed: 9310563
pmcid: 2127453
doi: 10.1136/bmj.315.7109.629
Allen NB, Lichtman JH, Cohen HW, Fang J, Brass LM, Alderman MH (2008) Vascular disease among hospitalized multiple sclerosis patients. Neuroepidemiology 30:234–238
pubmed: 18437030
doi: 10.1159/000128103
Christiansen CF, Christensen S, Farkas DK, Miret M, Sørensen HT, Pedersen L (2010) Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiology 35:267–274
pubmed: 20881430
doi: 10.1159/000320245
Lavela SL, Prohaska TR, Furner S, Weaver FM (2012) Chronic diseases in male veterans with multiple sclerosis. Prev Chronic Dis 9:E55
pubmed: 22321147
pmcid: 3346819
Zöller B, Li X, Sundquist J, Sundquist K (2012) Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. BMC Neurol 12:41
pubmed: 22708578
pmcid: 3430565
doi: 10.1186/1471-2377-12-41
Jadidi E, Mohammadi M, Moradi T (2013) High risk of cardiovascular diseases after diagnosis of multiple sclerosis. Mult Scler 19:1336–1340
pubmed: 23364857
doi: 10.1177/1352458513475833
Tseng CH, Huang WS, Lin CL, Chang YJ (2015) Increased risk of ischaemic stroke among patients with multiple sclerosis. Eur J Neurol 22:500–506
pubmed: 25443663
doi: 10.1111/ene.12598
Capkun G, Dahlke F, Lahoz R, Nordstrom B, Tilson HH, Cutter G, Bischof D, Moore A, Simeone J, Fraeman K, Bancken F, Geissbühler Y, Wagner M, Cohan S (2015) Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US Department of Defense administrative claims database. Mult Scler Relat Disord 4:546–554
pubmed: 26590661
doi: 10.1016/j.msard.2015.08.005
Thormann A, Magyari M, Koch-Henriksen N, Laursen B, Sørensen PS (2016) Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark. J Neurol 263:2484–2493
pubmed: 27699465
doi: 10.1007/s00415-016-8295-9
Persson R, Lee S, Yood MU, Wagner M, Minton N, Niemcryk S, Lindholm A, Evans A, Jick S (2020) Incident cardiovascular disease in patients diagnosed with multiple sclerosis: a multi-database study. Mult Scler Relat Disord 37:101423
pubmed: 32172996
doi: 10.1016/j.msard.2019.101423
Zulfiqar M, Qeadan F, Ikram A, Farooqui M, Richardson SP, Calder CS, Quadri SA, Mathur P, Ford C, Liera E, Snow H (2019) Intracerebral hemorrhage in multiple sclerosis: a retrospective cohort study. J Stroke Cerebrovasc Dis 28:267–275
pubmed: 30385221
doi: 10.1016/j.jstrokecerebrovasdis.2018.09.050
Castelo-Branco A, Chiesa F, Bengtsson CE, Lee S, Minton NN, Niemcryk S, Lindholm A, Rosenlund M, Piehl F, Montgomery S (2020) Non-infectious comorbidity in patients with multiple sclerosis: a national cohort study in Sweden. Mult Scler J Exp Transl Clin 6:2055217320947761
pubmed: 32864156
pmcid: 7430080
Tadić D, Grgić S, Dominović-Kovačević A, Nazalević-Bursać M, Mavija S, Đajić V (2022) Vascular comorbidities in patients with multiple sclerosis and their impact on physical disability. Med Glas (Zenica) 19:166–172
Cho EB, Yeo Y, Jung JH, Jeong SM, Han KD, Shin DW, Min JH (2022) Risk of stroke in multiple sclerosis and neuromyelitis optic spectrum disorder: a Nationwide cohort study in South Korea. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2022-329628
doi: 10.1136/jnnp-2022-329628
pubmed: 36028308
Christiansen CF (2012) Risk of vascular disease in patients with multiple sclerosis: a review. Neurol Res 34:746–753
pubmed: 22709796
doi: 10.1179/1743132812Y.0000000051
Veldhuijzen van Zanten JJ, Pilutti LA, Duda JL, Motl RW (2016) Sedentary behaviour in people with multiple sclerosis: Is it time to stand up against MS? Mult Scler 22:1250–1256
pubmed: 27072688
doi: 10.1177/1352458516644340
Roshanisefat H, Bahmanyar S, Hillert J, Olsson T, Montgomery S (2014) Multiple sclerosis clinical course and cardiovascular disease risk - Swedish cohort study. Eur J Neurol 21:e1353–e1388
doi: 10.1111/ene.12518
Thormann A, Sørensen PS, Koch-Henriksen N, Laursen B, Magyari M (2017) Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality. Neurology 89:1668–1675
pubmed: 28931645
doi: 10.1212/WNL.0000000000004508
Racosta JM, Sposato LA, Morrow SA, Cipriano L, Kimpinski K, Kremenchutzky M (2015) Cardiovascular autonomic dysfunction in multiple sclerosis: a meta-analysis. Mult Scler Relat Disord 4:104–111
pubmed: 25787186
doi: 10.1016/j.msard.2015.02.002
Tian Z, Song Y, Yao Y, Guo J, Gong Z, Wang Z (2020) Genetic etiology shared by multiple sclerosis and ischemic stroke. Front Genet 11:646
pubmed: 32719717
pmcid: 7348066
doi: 10.3389/fgene.2020.00646
Zeng R, Jiang R, Huang W, Wang J, Zhang L, Ma Y, Wu Y, Meng M, Lan H, Lian Q, Leung FW, Sha W, Chen H (2023) Dissecting shared genetic architecture between obesity and multiple sclerosis. EBioMedicine 93:104647
pubmed: 37300932
pmcid: 10363440
doi: 10.1016/j.ebiom.2023.104647
Palladino R, Chataway J, Majeed A, Marrie RA (2021) Interface of multiple sclerosis, depression, vascular disease, and mortality: a population-based matched cohort study. Neurology 97:e1322–e1333
pubmed: 34470802
pmcid: 8480403
doi: 10.1212/WNL.0000000000012610
Palladino R, Marrie RA, Majeed A, Chataway J (2020) Evaluating the risk of macrovascular events and mortality among people with multiple sclerosis in England. JAMA Neurol 77:820–828
pubmed: 32364569
doi: 10.1001/jamaneurol.2020.0664
Senzaki K, Okada Y, Ochi H, Ochi M, Takei SI, Miura S, Igase M, Ohyagi Y (2021) Vascular endothelial dysfunction associated with severity in multiple sclerosis. Mult Scler Relat Disord 54:103135
pubmed: 34274738
doi: 10.1016/j.msard.2021.103135
Al-Yafeai Z, Carvajal-González A, Abduljabar H, Arvas M, Patel S, Patel N (2022) Novel multiple sclerosis agents-associated cardiotoxicity: a real-world pharmacovigilance study. Int J Cardiol 362:153–157
pubmed: 35643216
doi: 10.1016/j.ijcard.2022.05.052
Najafian J, Nasri A, Etemadifar M, Salehzadeh F (2019) Late Cardiotoxicity in MS patients treated with mitoxantrone. Int J Prev Med 10:211
pubmed: 31921403
pmcid: 6941302
doi: 10.4103/ijpvm.IJPVM_477_17
Sánchez-Soblechero A, Cuello JP, Martínez Ginés ML, Lozano Ros A, Romero Delgado F, De Andrés C, Goicochea Briceño H, García Domínguez JM (2022) Recurrent intracranial hemorrhage in a patient with relapsing multiple sclerosis under interferon-β therapy. Neurologia (Engl Ed) 37:77–79
pubmed: 35074194
doi: 10.1016/j.nrl.2021.02.002
Azevedo CJ, Kutz C, Dix A, Boster A, Sanossian N, Kaplan J (2019) Intracerebral haemorrhage during alemtuzumab administration. Lancet Neurol 18:329–331
pubmed: 30777657
doi: 10.1016/S1474-4422(19)30076-6
Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG, Abbasifard M, Abbasi-Kangevari M, Abd-Allah F, Abedi V (2021) Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol 20:795–820
doi: 10.1016/S1474-4422(21)00252-0
Sati P, Oh J, Constable RT, Evangelou N, Guttmann CR, Henry RG, Klawiter EC, Mainero C, Massacesi L, McFarland H, Nelson F, Ontaneda D, Rauscher A, Rooney WD, Samaraweera AP, Shinohara RT, Sobel RA, Solomon AJ, Treaba CA, Wuerfel J, Zivadinov R, Sicotte NL, Pelletier D, Reich DS (2016) The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol 12:714–722
pubmed: 27834394
doi: 10.1038/nrneurol.2016.166
Zhang R, Li Q, Zhou Y, Yan S, Zhang M, Lou M (2019) The relationship between deep medullary veins score and the severity and distribution of intracranial microbleeds. Neuroimage Clin 23:101830
pubmed: 31039526
pmcid: 6529678
doi: 10.1016/j.nicl.2019.101830
Xu J, Lupu F, Esmon CT (2010) Inflammation, innate immunity and blood coagulation. Hamostaseologie 30(5–6):8–9
Jilma B, Cvitko T, Winter-Fabry A, Petroczi K, Quehenberger P, Blann AD (2005) High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men. Thromb Haemost 94:797–801
pubmed: 16270633
doi: 10.1160/TH04-10-0652
Sternberg Z, Leung C, Sternberg D, Yu J, Hojnacki D (2014) Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis. Cardiovasc Ther 32:33–39
pubmed: 24119301
doi: 10.1111/1755-5922.12049
Hong Y, Tang HR, Ma M, Chen N, Xie X, He L (2019) Multiple sclerosis and stroke: a systematic review and meta-analysis. BMC Neurol 19:139
pubmed: 31234793
pmcid: 6591845
doi: 10.1186/s12883-019-1366-7
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41
pubmed: 7678184
doi: 10.1161/01.STR.24.1.35
Meretoja A, Strbian D, Putaala J, Curtze S, Haapaniemi E, Mustanoja S, Sairanen T, Satopää J, Silvennoinen H, Niemelä M, Kaste M, Tatlisumak T (2012) SMASH-U: a proposal for etiologic classification of intracerebral hemorrhage. Stroke 43:2592–2597
pubmed: 22858729
doi: 10.1161/STROKEAHA.112.661603